NASDAQ:TCRT Alaunos Therapeutics (TCRT) Stock Price, News & Analysis → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Free TCRT Stock Alerts $1.29 -0.01 (-0.77%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$1.26▼$1.3550-Day Range$1.09▼$2.3552-Week Range$0.66▼$10.47Volume13,033 shsAverage Volume172,120 shsMarket Capitalization$20.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Alaunos Therapeutics alerts: Email Address Ad Paradigm PressAI “wealth window” is closing June 25thToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]… About Alaunos Therapeutics Stock (NASDAQ:TCRT)Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.Read More TCRT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TCRT Stock News HeadlinesApril 12, 2024 | seekingalpha.comRevolution Medicines: An Expensive Shot At A Massive Market OpportunityApril 8, 2024 | investorplace.comTCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023May 9, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…April 1, 2024 | msn.comBiora Therapeutics announces $6M registered direct offering and concurrent private placementJanuary 31, 2024 | msn.comAlaunos Therapeutics Announces 1-for-15 Reverse Stock SplitJanuary 31, 2024 | investing.comWerewolf Therapeutics Inc (HOWL)December 28, 2023 | benzinga.comAlaunos Therapeutics Stock (NASDAQ:TCRT) Dividends: History, Yield and DatesNovember 14, 2023 | benzinga.comRecap: Alaunos Therapeutics Q3 EarningsMay 9, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…November 14, 2023 | investorplace.comWhy Is Alaunos Therapeutics (TCRT) Stock Up 14% Today?November 14, 2023 | finance.yahoo.comAlaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic AlternativesNovember 1, 2023 | morningstar.comAlaunos Therapeutics Inc TCRTAugust 15, 2023 | msn.comWhy Is Alaunos Therapeutics Sinking Today?August 14, 2023 | finance.yahoo.comAlaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic AlternativesJune 29, 2023 | finance.yahoo.comAlaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic MalignanciesJune 9, 2023 | benzinga.comAlaunos Therapeutics Stock (NASDAQ:TCRT), Insider Trading ActivityMay 26, 2023 | msn.comAlaunos slips 17% on Phase 1/2 data for cancer cell therapyMay 25, 2023 | finance.yahoo.comAlaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual MeetingMay 17, 2023 | uk.news.yahoo.comOne Alaunos Therapeutics Insider Raised Stake By 117% In Previous YearMay 15, 2023 | seekingalpha.comAlaunos Therapeutics upgraded to buy at Wainwright on multiple catalystsMay 13, 2023 | finance.yahoo.comAlaunos Therapeutics, Inc. (NASDAQ:TCRT) Q1 2023 Earnings Call TranscriptMay 11, 2023 | marketwatch.com8-K: Alaunos Therapeutics, Inc.May 10, 2023 | finanznachrichten.deAlaunos Therapeutics, Inc.: Alaunos Therapeutics Reports First Quarter 2023 Financial ResultsMay 10, 2023 | msn.comAlaunos Therapeutics GAAP EPS of -$0.04 in-lineMay 10, 2023 | msn.comRecap: Alaunos Therapeutics Q1 EarningsMay 10, 2023 | finance.yahoo.comAlaunos Therapeutics Reports First Quarter 2023 Financial ResultsMay 3, 2023 | finance.yahoo.comAlaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023See More Headlines Receive TCRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alaunos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TCRT CUSIPN/A CIK1107421 Webwww.alaunos.com Phone(346) 355-4099Fax617-241-2855Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.3988) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,140,000.00 Net MarginsN/A Pretax Margin-702,800.00% Return on Equity-196.96% Return on Assets-134.81% Debt Debt-to-Equity RatioN/A Current Ratio4.22 Quick Ratio4.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book3.31Miscellaneous Outstanding Shares16,010,000Free Float15,022,000Market Cap$20.65 million OptionableOptionable Beta-0.26 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Dale Curtis Hogue Jr. (Age 54)Interim CEO & Director Mr. Michael Wong (Age 44)Vice President of Finance & Principal Accounting Officer Key CompetitorsMEI PharmaNASDAQ:MEIPSol-Gel TechnologiesNASDAQ:SLGLBenitec BiopharmaNASDAQ:BNTCSynlogicNASDAQ:SYBXNanoViricidesNYSE:NNVCView All CompetitorsInsiders & InstitutionsMagnolia Capital Advisors LLCSold 376,812 shares on 5/2/2024Ownership: 0.154%Fortis Group Advisors LLCBought 13,999 shares on 4/30/2024Ownership: 0.087%MSD Partners L.P.Sold 7,575,758 shares on 2/20/2024Ownership: 94.402%Commerce BankSold 22,000 shares on 2/9/2024Ownership: 2.723%Kevin S Sr. BoyleSold 4,534 sharesTotal: $9,521.40 ($2.10/share)View All Insider TransactionsView All Institutional Transactions TCRT Stock Analysis - Frequently Asked Questions Should I buy or sell Alaunos Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alaunos Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TCRT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCRT, but not buy additional shares or sell existing shares. View TCRT analyst ratings or view top-rated stocks. How have TCRT shares performed in 2024? Alaunos Therapeutics' stock was trading at $1.0605 on January 1st, 2024. Since then, TCRT stock has increased by 21.6% and is now trading at $1.29. View the best growth stocks for 2024 here. How were Alaunos Therapeutics' earnings last quarter? Alaunos Therapeutics, Inc. (NASDAQ:TCRT) announced its earnings results on Tuesday, November, 14th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.45) by $0.15. When did Alaunos Therapeutics' stock split? Alaunos Therapeutics's stock reverse split on the morning of Thursday, February 1st 2024. The 1-15 reverse split was announced on Thursday, February 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Alaunos Therapeutics' major shareholders? Alaunos Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Magnolia Capital Advisors LLC (0.15%) and Fortis Group Advisors LLC (0.09%). Insiders that own company stock include Kevin S Sr Boyle and Robert W Postma. View institutional ownership trends. How do I buy shares of Alaunos Therapeutics? Shares of TCRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TCRT) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
